Comparison · NCT02622724-83c032e9
FP-1201-lyo 10 μg vs Placebo: Efficacy Endpoint: Mortality in Hospital
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. FP-1201-lyo 10 μg vs Placebo: Efficacy Endpoint: Mortality in Hospital. Trial comparisons, record NCT02622724-83c032e9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02622724-83c032e9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00694 | 0.00123 | 0.0383 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0246 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00694 | -0.0184 | 0.0383 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on FP-1201-lyo 10 μg than on Placebo | 144 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | FP-1201-lyo 10 μg | FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days. | 1 | 144 | OG000 |
| Group 2 | Placebo | Placebo for 6 days. | 0 | 152 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Efficacy Endpoint: Mortality in Hospital
- Description
- This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.
- Time frame
- Up to Day 28
- Population
- Full Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
- NCT number
- NCT02622724
- Phases
- PHASE3
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Interferon beta-1a, Placebo
- Lead sponsor
- Faron Pharmaceuticals Ltd
- Results first posted
- 2020-03-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02622724?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02622724-83c032e9